Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01160328 | Influence of Male Hormones on Regional Fat Metabolism | PHASE1 | COMPLETED | 39 | — | — | Jun 1, 2010 | Jan 1, 2013 | May 14, 2014 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Control Group | NO_INTERVENTION | Participants in this group will not receive any treatment. |
| Lupron Group | EXPERIMENTAL | Participants in this group will receive leuprolide acetate (Lupron) treatment for 7 weeks resulting in temporary decreases in testosterone levels. |
| Lupron & Testosterone Group | OTHER | Participants in this group will receive 7 weeks of leuprolide acetate (Lupron) treatment with testosterone gel (Androgel). |
| Name | Type | Description |
|---|---|---|
| Leuprolide | DRUG | 7.5 mg - 1 month depot, 2 doses over 7 weeks |
| Testosterone | DRUG | 7.5g - 1% testosterone gel, daily x 7 weeks |
Inclusion Criteria: * Healthy, weight stable individuals * BMI 20-29 kg/m2 Exclusion Criteria: * Smoking and tobacco use * Diabetes and other disease * Anti-depressants